Loading...
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
Obatoclax mesylate is an intravenously-administered drug under investigation in Phase I and II clinical trials as a novel anticancer therapeutic for hematological malignancies and solid tumors. Obatoclax was developed as a pan-inhibitor of antiapoptotic members of the B cell chronic lymphocytic leuk...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3601645/ https://ncbi.nlm.nih.gov/pubmed/23515850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S42568 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|